Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update.

ENPNewswire-August 1, 2022--Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

(C)2022 ENPublishing - http://www.enpublishing.co.uk

Release date- 29072022 - LONDON and RALEIGH, N.C. - Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 5684286:

+1-888-317-6003 for callers in the United States

+1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days.

Contact:

Verona Pharma plc

US

Tel: +1-833-417-0262

UK

Tel: +44 (0)203 283 4200

Victoria Stewart

Director

Investor Relations and Communications

E: info@veronapharma.com

Investor

Argot Partners

US

Tel: +1-212-600-1902

E: verona@argotpartners.com

Kimberly Minarovich

Michael Barron

Optimum Strategic Communications

Tel: +44 (0)203 882 9621

E: verona@optimumcomms.com

Mary Clark

Rebecca Noonan

Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT